OpenAI GPT-5.6 Set for Wider Release After U.S. Commerce Approval, Report Says 
Zhipu AI Raises HK$31.37 Billion in Discounted Share Sale to Accelerate AI Growth 
Nvidia Invests $500M in Firmus Technologies Ahead of Planned ASX IPO 
Bernstein Names IAG, Ryanair as Top European Airline Stocks Ahead of Earnings 
SK Hynix’s $28 Billion U.S. Share Sale Draws Massive Demand Amid AI Chip Boom 
Levi Strauss Raises 2026 Outlook After Q2 Earnings Beat, Shares Drop Despite Strong Results 
SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO 
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia 
Wolfspeed Sues Navitas Over GaN and SiC Patent Infringement 
Oil and LNG Tankers Turn Back as Strait of Hormuz Security Risks Escalate 
Mizuho’s Top U.S. Industrials Stocks: Why Corteva and Stanley Black & Decker Stand Out 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
Sino Biopharm Stock Rises After AstraZeneca Licensing Deal, GSK Partnership Expansion 
Netflix, Disney, YouTube Eye FIFA World Cup TV Rights in Multi-Billion Dollar Battle 
SK Hynix’s $28B U.S. IPO Draws Strong Demand as AI Chip Boom Fuels Investor Interest 
BHP Faces Port Hedland Strike Threat as Iron Ore Export Risks Grow 
CHESTERBROOK, Pa., April 26, 2018 -- Trevena, Inc. (NASDAQ:TRVN) today announced that it will host a conference call and webcast on Thursday, May 3, 2018 at 8:00 am EDT to review financial results for the quarter ended March 31, 2018 and to discuss recent corporate highlights.
To join the call, please dial-in at (855) 465-0180 (conference ID: 1350009).
To join a live audio webcast of the call, please visit the Investor Presentation section of the Company’s website (conference ID: 1350009). Following the conclusion of the call, the webcast will be available for replay for 30 days.
About Trevena
Trevena, Inc. is a biopharmaceutical company focused on providing better, safer therapies to patients in pain. The Company has leveraged breakthrough science to discover and develop its investigational product, oliceridine injection, for the management of moderate-to-severe acute pain. Oliceridine has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration, and is intended to provide healthcare providers an innovative new option for patients who require an intravenous opioid. The Company also has an early stage pipeline of new chemical entities targeting novel mechanisms of action, including TRV250 for acute migraine, neuropathic pain, and other indications.
Contacts
Trevena, Inc.
Investors:
Jonathan Violin, Ph.D.
Senior Vice President, Scientific Affairs & Investor Relations Officer
610-354-8840 x231
[email protected]
or
Media:
Public Relations
[email protected]
